News | Mammography | January 04, 2018

Overweight Women May Need More Frequent Mammograms

Swedish study finds women considered overweight by body mass index (BMI) have larger interval cancers

Overweight Women May Need More Frequent Mammograms

January 4, 2018 — Women with higher body mass index (BMI) face an increased risk of not detecting their breast tumor until it has become large, according to a study presented at the 2017 annual meeting of the Radiological Society of North America (RSNA) in Chicago in November. Researchers said the findings suggest that women with higher BMI may need shorter intervals between mammography screening exams.

BMI is a measure of body fat based on height and weight, with overweight defined as a BMI of 25 or more. High BMI is associated with a number of health risks, including diabetes and heart disease. However, BMI is not considered as part of breast cancer screening guidelines.

For the new study, conducted at Karolinska Institutet in Sweden, researchers set out to identify risk factors associated with tumors not being detected until larger than 2 centimeters (cm), or about the size of a peanut, and to examine the implications for long-term prognosis. The 2-cm size is important because it is one of the parameters used to separate stage I and stage II cancers. In addition, tumor size is known to be strongly associated with prognosis, according to study co-author Fredrik Strand, M.D., radiologist at the Karolinska University Hospital in Stockholm, Sweden.

Strand and colleagues studied 2,012 cases of invasive breast cancer that appeared from 2001 to 2008. The researchers followed the patients until the end of 2015, and looked for how disease progression was related to BMI and breast density.

For cancers detected at screening, both BMI and breast density were associated with having a large tumor at diagnosis. However, for interval cancers, or cancers detected within two years of a normal mammogram, only BMI was linked with having a large tumor. Women with higher BMI had worse prognosis than women with lower BMI among interval cancers. Breast density showed no significant association with disease progression.

Strand said the findings provide more information for physicians and patients when deciding about optimal screening approaches.

"Our study suggests that when a clinician presents the pros and cons of breast cancer screening to the patient, having high BMI should be an important 'pro' argument," he said. "In addition, our findings suggest that women with high BMI should consider shorter time intervals between screenings."

Besides the larger interval cancers, women with high BMI may have other factors that put them at risk for a worse prognosis, including the molecular composition of the tumors and hormone receptor expression levels that make them harder to treat, Strand added.

The study was carried out in Sweden, which has 18- to 24-month intervals between screenings — longer than the 12 months recommended by some U.S. organizations like the American Cancer Society, but not the 24-month screening interval recommended by the United States Preventive Services Task Force (USPSTF). In addition, there are fewer women with high BMI in Sweden than in the United States.

In the near future, Strand intends to look at how breast density is associated with delayed detection. Longer-term, he wants to study artificial intelligence as a way to triage mammographic screening examinations into different pipelines based on the risk of breast cancer and the detectability of a potential tumor.

Co-authors are Keith Humphreys, Ph.D., Johanna Holm, M.Sc., Mikael Eriksson, M.Sc., Sven Törnberg, M.D., Ph.D., Per Hall, M.D., Ph.D., Edward Azavedo, M.D., Ph.D., and Kamila Czene, Ph.D.

For more information: www.rsna.org

 

Key RSNA 2017 Study Presentations, Trends and Video

Related Content

Doctor-Patient Discussions Neglect Potential Harms of Lung Cancer Screening
News | Lung Cancer | August 15, 2018
August 15, 2018 — Although national guidelines advise doctors to discuss the benefits and harms of...
Illinois Governor Approves State Breast Density Reporting Bill Into Law
News | Breast Density | August 13, 2018
Illinois Gov. Bruce Rauner approved the Illinois Breast Density Reporting Law (Public Act 100-0749) on Aug. 10, 2018...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
iCAD Receives FDA Clearance of PowerLook Density Assessment for Digital Breast Tomosynthesis
Technology | Breast Density | August 08, 2018
iCAD announced U.S. Food and Drug Administration (FDA) clearance of its latest artificial intelligence (AI) software...
Cardiac Imaging Reveals Roots of Preeclampsia Damage in Pregnant Women
News | Women's Health | August 07, 2018
Johns Hopkins researchers say a heart imaging study of scores of pregnant women with the most severe and dangerous form...
Cardiac Monitoring a Higher Priority for High-Risk Breast Cancer Patients
News | Cardio-oncology | August 07, 2018
August 7, 2018 — While heart failure is an uncommon complication of...
Hologic Acquires Digital Specimen Radiography Company Faxitron Bioptics

VisionCT 3-D breast specimen-designated computed tomography (CT) system. Image courtesy of Faxitron Bioptics.

News | Breast Imaging | July 31, 2018
Hologic Inc. announced it has completed the acquisition of Faxitron Bioptics, a privately-held leader in digital...
Konica Minolta Hosting Lunch and Learn at 23rd Annual Mammography Meeting in Santa Fe
News | Breast Imaging | July 31, 2018
Konica Minolta Healthcare Americas Inc. will sponsor a lunch and learn featuring its Exa Mammo platform during the 23rd...
FDA Approves New Tomosynthesis Quality Control Tests for ACR Digital Mammography QC Manual
News | Mammography | July 30, 2018
The U.S. Food and Drug Administration (FDA) recently approved the American College of Radiology’s (ACR’s) amendment to...
The Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal. The FDA granted approval of the Sentimag System to Endomagnetics Inc.

The  Endomagnetics' Magtrace and Sentimag Magnetic Localization System uses magnetic detection during sentinel lymph node biopsy procedures to identify specific lymph nodes, known as sentinel lymph nodes, for surgical removal.

Technology | Women's Health | July 24, 2018
July 24, 2018 — The U.S.
Overlay Init